Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07123545 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Zhejiang University
149 trials monitored
See 4 trials at risk
Liver Cancer
1,512 trials monitored
See 63 trials at risk
The goal of this open-label, single-arm phase I/II clinical trial is to evaluate the feasibility, safety, and anti-tumor efficacy of the autologous neoantigen-specific T-cell therapy (iNeo-Vac-T01) in patients with advanced hepatocellular carcinoma who have failed second-line or later systemic therapies.
Trial Details
NCT Number NCT07123545
Lead Sponsor Zhejiang University
Collaborators: Hangzhou Neoantigen Therapeutics Co., Ltd.
Conditions Advanced Hepatocellular Carcinoma (HCC)
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov